ArticleJournal of clinical medicine2021
COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- [The most frequent febrile syndromes and autoinflammatory diseases in adulthood].Zeitschrift fur Rheumatologie · 2024Review
- Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever.Pharmacological research · 2022Article
- Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children.Journal of clinical medicine · 2022Article
- Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran.Clinical rheumatology · 2022Article
- Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels.Frontiers in pediatrics · 2022Review
- Autoinflammation It Is!Journal of clinical medicine · 2021Article
- Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.International journal of molecular sciences · 2021Review
- Adamantiades-Behçet's disease (Behçet's disease) and COVID-19.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Anti-COVID-19 measurements for hidradenitis suppurativa patients.Experimental dermatology · 2021Article
- Lockdown effects on a patient receiving immunosuppression for unilateral HLA- B27 associated uveitis during COVID-19 pandemic.Indian journal of ophthalmology · 2021Article
- Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists.Rheumatology international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 disease increases interleukin (IL)-1β release. Anti-IL-1-treatment is effective in IL-1-mediated autoinflammatory diseases (AID). This case series presents COVID-19 in patients with IL-1-mediated and unclassified AID with immunosuppressive therapy (IT). Patient 1 is a 34-year-old woman with an unclassified AID and methotrexate. Patients 2 and 3 (14-year-old girl and 12-year-old boy, respectively) have a Cryopyrin-Associated Periodic Syndrome (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.